PharmaVitae explores Mitsubishi Tanabe’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Teva’s prescription pharmaceutical performance and outlook over 2019–29.
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Eisai’s prescription pharmaceutical performance and outlook over 2019–29.
PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.
PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.
PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.
PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.
Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!